Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry

Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry

(1) Background: Immune checkpoint inhibitors have improved the prognosis of patients with advanced melanoma. Published data suggested that the objective response rates appear to be superior in patients who developed immune-related adverse events (irAEs). (2) The primary aim of this cohort study was...

Full description

Bibliographic Details
Main Authors: Lina María Serna-Higuita, Teresa Amaral, Andrea Forschner, Ulrike Leiter, Lukas Flatz, Olivia Seeber, Ioannis Thomas, Claus Garbe, Thomas Kurt Eigentler, Peter Martus
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Cancers
Subjects:
melanoma
immune-related adverse events
response
survival
immunotherapy
anti-PD-1
Online Access:https://www.mdpi.com/2072-6694/13/23/6141

Internet

https://www.mdpi.com/2072-6694/13/23/6141

Similar Items